Assessment of genotoxicity of aflatoxin M1 and B1 contaminated milks after in vitro human digestion

Introduction - Milk is considered a complete food from the nutritional point of view. Milk can be exposed to various types of contamination, such as mycotoxins. These metabolites are naturally occurring toxic compounds produced by fungi. Several studies on milk samples have reported the presence of aflatoxin B1 (AFB1) and M1 (AFM1), due to the high incidence in samples intended for human consumption, carcinogenicity proven AFB1 and resistance of the contaminants to the process of digestion, making those available for intestinal absorption. Considering these aspects, the objective of this study was to evaluate the genotoxicity of milk samples contaminated by AFB1 and AFM1 before and after the action of lactic acid bacteria using Caco-2 intestinal human cells.

Endocrine disruptors mixtures: the real scenario of human exposure

Endocrine disrupting chemicals (EDCs) are exogenous agents that have the ability to interfere with/or mimic estrogenic hormones and, therefore can simultaneously and differentially trigger specific signaling pathways responsible for the nature and magnitude of biological responses in diverse cell types. Human exposure to EDCs, particularly at low-doses, is ubiquitous, persistent and occurs in complex mixtures. These compounds can bioaccumulate in lipid compartments of tissues forming a mixed “body burden” of contaminants of different origins. Although the independent action of chemicals has been considered the main principle in EDCs mixture toxicity, several effects cannot be predicted when analyzing single compounds individually. Based in a revision of the literature, focused in studies that evaluated EDCs mixtures, we hypothesize the scenario of a pregnant woman environmentally exposed to three different EDCs as a potential real scenario of human exposure supported by data describing where exposure to these compounds occur.

Comet assay as a human biomonitoring tool: application in occupational exposure to antineoplastic drugs

Antineoplastic drugs are a heterogeneous group of chemicals used in the treatment of cancer, and have been proved by IARC to be mutagens, carcinogens and teratogens agents. In general, chemicals that interact directly with DNA by biding covalently or by intercalating, or indirectly by interfering with DNA synthesis, were among the first chemotherapeutics developed. Also, these drugs can induce reactive oxygen species that can lead to DNA damage and, consequently, mutations. These drugs are often used in combination to achieve synergistic effects on tumour cells resulting from their differing modes of action. However, most if not all of these chemical agents are generally nonselective and, along with tumour cells, normal cells may undergo cytotoxic/genotoxic damage. The in vivo exposure to antineoplastic drugs has been shown to induce different types of lesions in DNA, depending on the particular stage of cell cycle at the time of treatment. Besides the patients that use these drugs as a treatment, workers that handle and/or administer these drugs can be exposed to these substances; namely pharmacy, and nursing personnel in hospital context.